{"name":"Sentynl Therapeutics, Inc.","slug":"sentynl-therapeutics-inc","ticker":"","exchange":"","domain":"sentynl.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"copper histidinate","genericName":"copper histidinate","slug":"copper-histidinate","indication":"Copper deficiency due to malabsorption (including Menkes disease and related copper transport disorders)","status":"marketed"}]}],"pipeline":[{"name":"copper histidinate","genericName":"copper histidinate","slug":"copper-histidinate","phase":"marketed","mechanism":"Copper histidinate provides bioavailable copper to restore deficient copper levels in patients with copper malabsorption or deficiency.","indications":["Copper deficiency due to malabsorption (including Menkes disease and related copper transport disorders)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQN01tV05keG1mNFhwd2tITi1EM2s5T1VYakJNb2hUNTJ1SU9hWlUyLUszWVh1a093QlJOMkt4RGRfY0Z2LXBuUGlJV05qMXc2UUFFbENhcldiaUJjN0Y0N0xZbDhQZlZXTFlQODlfNmxNdGxfU1JDcXVYT0QzR3ppODFtNXI1UUhaWDlvRUNUV2xkUjU3Q2k5UUFpVXYwRFNXME0wVFlvbUc1dllHU1V1eHl2cThkYnk0VzNIamVubTBzenA0ZmlBTnlRaw?oc=5","date":"2026-03-31","type":"pipeline","source":"Sahm","summary":"Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - Sahm","headline":"Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPRmt4MDJfWE42bWdPbVc4Tm5VX20xTnNidVZQRzBUMHlITjZuTDh5dW9rM254ak41Qzh5Qi1PZ1RRbkQ1dl9ud0FyVnl5QmVoTHNNNVg0WDZ6ai1xWmZtMm9TNU5NM3hWczhMYU9WZFAzdmg2b0NNeFFMY29QV3JCZllCdVBFbWFoNFhQU3YwXzhGQVQ1aGpObTFnbFQzb0Fzby13andENEIzUQ?oc=5","date":"2026-01-13","type":"regulatory","source":"Fierce Pharma","summary":"FDA blesses Sentynl and Cyprium's Zycubo as 1st treatment for Menkes disease - Fierce Pharma","headline":"FDA blesses Sentynl and Cyprium's Zycubo as 1st treatment for Menkes disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNNm5sdjlKTFo3RWlHYkZjZ2NuTkRvZWRQMWNBU0lCSjV3a0FoS2ZvVkVkQlBhd0duVHNfM3o4Rnhaa2x3WWdnZmVGMzJaSVVzc3h3dWtJbU1Jam4wZ1BQbUJLTk1GcnNIbENXeWQ3YU9LSXp4VEQtWDVyNFA5Q21RaXd2X2hqNGl1R3dtVGM3X0sxdGd6RnowdXN6dnFxT3NHRUE?oc=5","date":"2026-01-13","type":"regulatory","source":"BioWorld News","summary":"US FDA clears Sentynl’s Zycubo as first treatment for Menkes - BioWorld News","headline":"US FDA clears Sentynl’s Zycubo as first treatment for Menkes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPamFxWUk4QjNLNnJjZ3VPQXdRSS04dWRTeGJSUmlIMzBuUzk1azdVV0RiWmM5R1R2UGpTVzQ0dG5Tc1FnYjUxZVJsWEwtM1J4NmNpNTlNVTRaRVh1bGFsSlJkTHlOU0J0M2tZUmNvXzFwa2d4ZTNwa2lUbE96Ri0zQVZ4WTRYM1BuNExOLVBqYW8walRselFyb1FGZE1qaFRCRUx4VlB6NjdMZmg5TmZiNnlsY21yRktNdXZPdjRjNEZ6SVhOUnRhYm9TV24?oc=5","date":"2026-01-13","type":"regulatory","source":"PR Newswire","summary":"Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate) - PR Newswire","headline":"Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOR0k2RDhab1l0SVVhZ2FGR2IySVR0YkpTT1luMnF2VkR5NWRHbV9KcktDWkY3TUhOeUtBUm96Si1Ob0hrMnBkdndYdHYtbUtTS2I4emMwNXlfcW1XZ1pMaGVZUUlNVy16bEZ4a1NLb01OOHNVTGQ2RG1GVWpmNnAyLVUyc0NCNVYz?oc=5","date":"2026-01-13","type":"regulatory","source":"pharmaphorum","summary":"Sentynl gets first FDA approval for rare disease Menkes - pharmaphorum","headline":"Sentynl gets first FDA approval for rare disease Menkes","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNRGtsX0dnQ0pwa2J6RFF0VlpUVWs3QnpfTGRVTmljNkRleUk4MmtfX2R6NS14RDlIWlVoaF9qMzh2al9wZkFzbFo4NlJRb1pJYnExakFQWTJkU2N4bFMzanlNQUN3dExPcG5sRlRzc3BWSkxsUmNScTZEc2ZZRDNoN2hNa0VQNHlNc3FuNXFfeVhsX215RFItdEM1RVdhOWFmNW5mUmc0VmI2N0VF?oc=5","date":"2025-10-01","type":"pipeline","source":"PR Newswire","summary":"Sentynl Therapeutics updates on its NDA for CUTX-101 - PR Newswire","headline":"Sentynl Therapeutics updates on its NDA for CUTX-101","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxPWlVyQ1RnRUE3VGpoUUo0djNXSDN3c2U1NU0zSmRjeWMtVlMtX1ZhbEtrSWdoOHRnMFdkU2tpNXNBMHh5R0lKMV90SU4zSm14NGxZdXdZb3RwSkMyaHNSdmRMbnRZblU5dFRKeEVQQkxQZUxqdUJ6Y2JlRUl4Wll2cHZkczA5MUpLakUtNGluY0VaN2dQbXU2d0dqWWllYWxxTVNYdTlBYnh4TDlaVGYtX3d0S2N0aTgtWVRhVWFTMEJiYXhMTy0yQzFDeEhzejhTSUJxR2c5d1hjaWRQWWxxZFB1c1JSTDdhTXF5UzFvaEVyM3RxREx1MWIxbVVyYks2MWVrN2NKUGtrbUdwbi1NM2tnb0VEdUZMd08zdEpkUWs3bi1ZenVsY2dFVk9IZ0Q2c3Y0ZVBhdUtfZVhTbDdZ?oc=5","date":"2025-09-24","type":"pipeline","source":"GlobeNewswire","summary":"Er-Kim Enters Commercialization Agreement with Sentynl - GlobeNewswire","headline":"Er-Kim Enters Commercialization Agreement with Sentynl","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-07","type":"regulatory","source":"Medical Dialogues","summary":"Zydus Lifesciences arm application for Menkes disease treatment gets USFDA priority review - Medical Dialogues","headline":"Zydus Lifesciences arm application for Menkes disease treatment gets USFDA priority review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOaXZTMnVSbWtya29nLUkzRGZOMkpIWjJfU1k4NS01SmJwOXItMXNzd3NTNFl5UWlPQUc0cE9zUmViMExOVFpvd1BFVENwamhJNzdZcUQxVGd1SDVOVkZsMFVBUVh6ZHlBd3BfcHAxYUNhSVdFTEV4Y1VTR0xhMkpTSVlwMFM?oc=5","date":"2024-05-06","type":"deal","source":"Pharmaceutical Technology","summary":"Sentynl acquires Eiger’s Zokinvy for progeria treatment - Pharmaceutical Technology","headline":"Sentynl acquires Eiger’s Zokinvy for progeria treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPQzVZNGVxajdIT2xuNnlIeGlIMkNwLUo5dHB5NE5FS09NME5FaHdxU0N1RFdGT3poUUdtU3RqM2R0ZGdXVWhGRGZ4dzVDZG9uTndsSHZucTdpTUpwQXdITjdzX0tSU25DWUdvXzNzWDA2T19wY3NZNDd0MjNjZ0tpZmlLcFFNbW1OQ2M5eVhRNjk1dE5OZGs2bHNMQjRRX3NacWJrNmw0MmhnV3ZHSWR1N1JMT0VCbjh0OW5MeWxHRlpadw?oc=5","date":"2023-09-25","type":"pipeline","source":"Fierce Pharma","summary":"Why Pharma Should Pay Attention to – and Be Part of – Rapid Whole Genome Sequencing Advancement - Fierce Pharma","headline":"Why Pharma Should Pay Attention to – and Be Part of – Rapid Whole Genome Sequencing Advancement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQWm1yTExTSlp5Vkl2NnJ1TU8tcEFCQVVUSjNpZHJoQ2p0SzlaN1JEQ2gzLU44Y0NqVUV0RGd1RVZpZWpTaUc4N3FzSkQ5QUxlM2dYY0t6RWtaUTNLUWcyQ3puZlVCR014a2Fmb2NlYXJOaTRyamxGa1lDeVlheWhuRUxFajFFbW91RllBVEhxXzlKcERSb21xQXBDcWFSTUI3RjJGR0hVX3NCV2ZCcFJJblpNSEZhSUl0dmxzRGtLa0dpWmpxSnhWdzQwVEpXTldQNFFDR3FQZWpSckVKTVlIRnhQc3VOV1lJbEwwdDJTWHRFWk5yWEpfVlRUTFlSVE1JZnFWalVTd0Ixa2RkME5OVGNSTGlwM2J2V2htNA?oc=5","date":"2022-03-08","type":"pipeline","source":"GlobeNewswire","summary":"BridgeBio Pharma and Sentynl Therapeutics Announce Asset - GlobeNewswire","headline":"BridgeBio Pharma and Sentynl Therapeutics Announce Asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPZWUzQjR6bzVHWjRMNnZ2akZJRmZUSnJnNHFETmplR3NjS3FVWTJnSkdZM1NmNWZoalowRHhzOElBTE40TlJIUXEydnRMNllOTFE4SUFjcVpwOHk1TDMySFljMVJLWGFaVjY0d0Q4WnNjQ2FzN3JSU25HaWxyRms1aE8zLVJWMEs0aXJJaE52NzlsOFNsdmFSdURkQTJxMV9zWUstcm1B?oc=5","date":"2021-02-24","type":"pipeline","source":"Contract Pharma","summary":"Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement - Contract Pharma","headline":"Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}